374 related articles for article (PubMed ID: 31920383)
1. T-Regulatory Cells In Tumor Progression And Therapy.
Verma A; Mathur R; Farooque A; Kaul V; Gupta S; Dwarakanath BS
Cancer Manag Res; 2019; 11():10731-10747. PubMed ID: 31920383
[TBL] [Abstract][Full Text] [Related]
2. Targeting regulatory T cells for improving cancer therapy: Challenges and prospects.
Dwarakanath BS; Farooque A; Gupta S
Cancer Rep (Hoboken); 2018 Jun; 1(1):e21105. PubMed ID: 32729245
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T cells: a review.
Dasgupta A; Saxena R
Natl Med J India; 2012; 25(6):341-51. PubMed ID: 23998865
[TBL] [Abstract][Full Text] [Related]
4. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
5. Induced regulatory T cells in inhibitory microenvironments created by cancer.
Whiteside TL
Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
7. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
8. Targeting regulatory T cells for immunotherapy in melanoma.
Huang L; Guo Y; Liu S; Wang H; Zhu J; Ou L; Xu X
Mol Biomed; 2021; 2(1):11. PubMed ID: 34806028
[TBL] [Abstract][Full Text] [Related]
9. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy.
Kim JH; Kim BS; Lee SK
Immune Netw; 2020 Feb; 20(1):e4. PubMed ID: 32158592
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.
González-Navajas JM; Fan DD; Yang S; Yang FM; Lozano-Ruiz B; Shen L; Lee J
Front Immunol; 2021; 12():625783. PubMed ID: 33717139
[TBL] [Abstract][Full Text] [Related]
12. Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy.
Kolb HR; Borcherding N; Zhang W
Adv Exp Med Biol; 2021; 1278():229-256. PubMed ID: 33523451
[TBL] [Abstract][Full Text] [Related]
13. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
14. Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.
Kumar P; Saini S; Khan S; Surendra Lele S; Prabhakar BS
Cell Immunol; 2019 May; 339():41-49. PubMed ID: 30482489
[TBL] [Abstract][Full Text] [Related]
15. Role of heterogeneous regulatory T cells in the tumor microenvironment.
Wei T; Zhong W; Li Q
Pharmacol Res; 2020 Mar; 153():104659. PubMed ID: 31982490
[TBL] [Abstract][Full Text] [Related]
16. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Kochin V; Nishikawa H
Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.
Tsyklauri O; Chadimova T; Niederlova V; Kovarova J; Michalik J; Malatova I; Janusova S; Ivashchenko O; Rossez H; Drobek A; Vecerova H; Galati V; Kovar M; Stepanek O
Elife; 2023 Jan; 12():. PubMed ID: 36705564
[TBL] [Abstract][Full Text] [Related]
18. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.
Karpisheh V; Mousavi SM; Naghavi Sheykholeslami P; Fathi M; Mohammadpour Saray M; Aghebati-Maleki L; Jafari R; Majidi Zolbanin N; Jadidi-Niaragh F
Life Sci; 2021 Nov; 284():119132. PubMed ID: 33513396
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses.
Hoelzinger DB; Smith SE; Mirza N; Dominguez AL; Manrique SZ; Lustgarten J
J Immunol; 2010 Jun; 184(12):6833-42. PubMed ID: 20483762
[TBL] [Abstract][Full Text] [Related]
20. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
